Djordje S Popovic, Edita Stokic, Stevan L Popovic. Curr Pharm Des 2015
Times Cited: 4
Times Cited: 4
Times Cited
Times Co-cited
Similarity
GLP-1 Agonists in Type 1 Diabetes Mellitus.
Kristin M Janzen, Taylor D Steuber, Sarah A Nisly. Ann Pharmacother 2016
Kristin M Janzen, Taylor D Steuber, Sarah A Nisly. Ann Pharmacother 2016
50
Adjunctive Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Type 1 Diabetes Mellitus.
Kira B Harris, Cassie L Boland. Pharmacotherapy 2016
Kira B Harris, Cassie L Boland. Pharmacotherapy 2016
50
Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
Anne L Peters, Elizabeth O Buschur, John B Buse, Pejman Cohan, Jamie C Diner, Irl B Hirsch. Diabetes Care 2015
Anne L Peters, Elizabeth O Buschur, John B Buse, Pejman Cohan, Jamie C Diner, Irl B Hirsch. Diabetes Care 2015
50
Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis.
Daniel J Drucker. Endocrinology 2003
Daniel J Drucker. Endocrinology 2003
50
Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists.
Urd Kielgast, Jens J Holst, Sten Madsbad. Curr Diabetes Rev 2009
Urd Kielgast, Jens J Holst, Sten Madsbad. Curr Diabetes Rev 2009
50
Treatment of diabetic complications: how can we learn by seeking and blundering?
K Pafili, N Papanas, E Maltezos. Angiology 2015
K Pafili, N Papanas, E Maltezos. Angiology 2015
25
Obesity and type 1 diabetes mellitus management.
J J Chillarón, D Benaiges, L Mañé, J Pedro-Botet, J A Flores Le-Roux. Minerva Endocrinol 2015
J J Chillarón, D Benaiges, L Mañé, J Pedro-Botet, J A Flores Le-Roux. Minerva Endocrinol 2015
25
Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors.
Julio Rosenstock, Ele Ferrannini. Diabetes Care 2015
Julio Rosenstock, Ele Ferrannini. Diabetes Care 2015
25
The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: A systematic review and meta-analysis.
Heming Guo, Chen Fang, Yun Huang, Yufang Pei, Linqi Chen, Ji Hu. Diabetes Res Clin Pract 2016
Heming Guo, Chen Fang, Yun Huang, Yufang Pei, Linqi Chen, Ji Hu. Diabetes Res Clin Pract 2016
25
Preliminary studies related to anti-interleukin-1β therapy in children with newly diagnosed type 1 diabetes.
Kathryn M Sumpter, Soumya Adhikari, Ellen K Grishman, Perrin C White. Pediatr Diabetes 2011
Kathryn M Sumpter, Soumya Adhikari, Ellen K Grishman, Perrin C White. Pediatr Diabetes 2011
25
The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges.
M Davies. Int J Obes Relat Metab Disord 2004
M Davies. Int J Obes Relat Metab Disord 2004
25
Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Pablo Lapuerta, Brian Zambrowicz, Paul Strumph, Arthur Sands. Diab Vasc Dis Res 2015
Pablo Lapuerta, Brian Zambrowicz, Paul Strumph, Arthur Sands. Diab Vasc Dis Res 2015
25
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis.
Sunder Mudaliar, Sindura Alloju, Robert R Henry. Diabetes Care 2016
Sunder Mudaliar, Sindura Alloju, Robert R Henry. Diabetes Care 2016
25
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
25
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.
Donald E Kohan, Paola Fioretto, Weihua Tang, James F List. Kidney Int 2014
Donald E Kohan, Paola Fioretto, Weihua Tang, James F List. Kidney Int 2014
25
Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.
B Komoroski, N Vachharajani, Y Feng, L Li, D Kornhauser, M Pfister. Clin Pharmacol Ther 2009
B Komoroski, N Vachharajani, Y Feng, L Li, D Kornhauser, M Pfister. Clin Pharmacol Ther 2009
25
SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.
Monika Misra. J Pharm Pharmacol 2013
Monika Misra. J Pharm Pharmacol 2013
25
Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time?
Kalliopi Pafili, Nikolaos Papanas. Expert Opin Pharmacother 2015
Kalliopi Pafili, Nikolaos Papanas. Expert Opin Pharmacother 2015
25
Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus.
W Tang, T A Leil, E Johnsson, D W Boulton, F LaCreta. Diabetes Obes Metab 2016
W Tang, T A Leil, E Johnsson, D W Boulton, F LaCreta. Diabetes Obes Metab 2016
25
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
Arthur T Sands, Brian P Zambrowicz, Julio Rosenstock, Pablo Lapuerta, Bruce W Bode, Satish K Garg, John B Buse, Phillip Banks, Rubina Heptulla, Marc Rendell,[...]. Diabetes Care 2015
Arthur T Sands, Brian P Zambrowicz, Julio Rosenstock, Pablo Lapuerta, Bruce W Bode, Satish K Garg, John B Buse, Phillip Banks, Rubina Heptulla, Marc Rendell,[...]. Diabetes Care 2015
25
The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.
Volker Vallon. Annu Rev Med 2015
Volker Vallon. Annu Rev Med 2015
25
Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.
B Komoroski, N Vachharajani, D Boulton, D Kornhauser, M Geraldes, L Li, M Pfister. Clin Pharmacol Ther 2009
B Komoroski, N Vachharajani, D Boulton, D Kornhauser, M Geraldes, L Li, M Pfister. Clin Pharmacol Ther 2009
25
Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes.
Nitesh D Kuhadiya, Husam Ghanim, Aditya Mehta, Manisha Garg, Salman Khan, Jeanne Hejna, Barrett Torre, Antoine Makdissi, Ajay Chaudhuri, Manav Batra,[...]. J Clin Endocrinol Metab 2016
Nitesh D Kuhadiya, Husam Ghanim, Aditya Mehta, Manisha Garg, Salman Khan, Jeanne Hejna, Barrett Torre, Antoine Makdissi, Ajay Chaudhuri, Manav Batra,[...]. J Clin Endocrinol Metab 2016
25
Complications of Diabetes.
Konstantinos Papatheodorou, Maciej Banach, Michael Edmonds, Nikolaos Papanas, Dimitrios Papazoglou. J Diabetes Res 2015
Konstantinos Papatheodorou, Maciej Banach, Michael Edmonds, Nikolaos Papanas, Dimitrios Papazoglou. J Diabetes Res 2015
25
The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema.
Stanley S Schwartz, Solomon Epstein, Barbara E Corkey, Struan F A Grant, James R Gavin, Richard B Aguilar. Diabetes Care 2016
Stanley S Schwartz, Solomon Epstein, Barbara E Corkey, Struan F A Grant, James R Gavin, Richard B Aguilar. Diabetes Care 2016
25
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Serge A Jabbour, Elise Hardy, Jennifer Sugg, Shamik Parikh. Diabetes Care 2014
Serge A Jabbour, Elise Hardy, Jennifer Sugg, Shamik Parikh. Diabetes Care 2014
25
GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach.
Isabella Crisci, Michele Aragona, Konstantina Savvina Politi, Giuseppe Daniele, Stefano Del Prato. Acta Diabetol 2015
Isabella Crisci, Michele Aragona, Konstantina Savvina Politi, Giuseppe Daniele, Stefano Del Prato. Acta Diabetol 2015
25
Tofogliflozin: the road goes ever on.
Kalliopi Pafili, Nikolaos Papanas. Expert Opin Pharmacother 2014
Kalliopi Pafili, Nikolaos Papanas. Expert Opin Pharmacother 2014
25
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
Clifford J Bailey, Jorge L Gross, Anne Pieters, Arnaud Bastien, James F List. Lancet 2010
Clifford J Bailey, Jorge L Gross, Anne Pieters, Arnaud Bastien, James F List. Lancet 2010
25
The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats.
F R Macdonald, J E Peel, H B Jones, R M Mayers, L Westgate, J M Whaley, S M Poucher. Diabetes Obes Metab 2010
F R Macdonald, J E Peel, H B Jones, R M Mayers, L Westgate, J M Whaley, S M Poucher. Diabetes Obes Metab 2010
25
Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Robert R Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List, Steven C Griffen. Diabetes Care 2015
Robert R Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List, Steven C Griffen. Diabetes Care 2015
25
Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus.
Hector E Tamez, Alejandra L Tamez, Lucas A Garza, Mayra I Hernandez, Ana C Polanco. J Diabetes Metab Disord 2015
Hector E Tamez, Alejandra L Tamez, Lucas A Garza, Mayra I Hernandez, Ana C Polanco. J Diabetes Metab Disord 2015
25
Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes.
L Laffel. Diabetes Metab Res Rev 1999
L Laffel. Diabetes Metab Res Rev 1999
25
Four-year clinical remission of type 1 diabetes mellitus in two patients treated with sitagliptin and vitamin D3.
Marcelo Maia Pinheiro, Felipe Moura Maia Pinheiro, Margareth Afonso Torres. Endocrinol Diabetes Metab Case Rep 2016
Marcelo Maia Pinheiro, Felipe Moura Maia Pinheiro, Margareth Afonso Torres. Endocrinol Diabetes Metab Case Rep 2016
25
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
Caroline Bonner, Julie Kerr-Conte, Valéry Gmyr, Gurvan Queniat, Ericka Moerman, Julien Thévenet, Cédric Beaucamps, Nathalie Delalleau, Iuliana Popescu, Willy J Malaisse,[...]. Nat Med 2015
Caroline Bonner, Julie Kerr-Conte, Valéry Gmyr, Gurvan Queniat, Ericka Moerman, Julien Thévenet, Cédric Beaucamps, Nathalie Delalleau, Iuliana Popescu, Willy J Malaisse,[...]. Nat Med 2015
25
Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study.
Robert R Henry, Paresh Dandona, Jeremy Pettus, Sunder Mudaliar, John Xu, Lars Hansen. Diabetes Obes Metab 2017
Robert R Henry, Paresh Dandona, Jeremy Pettus, Sunder Mudaliar, John Xu, Lars Hansen. Diabetes Obes Metab 2017
25
A fairy tale of modern insulin therapy in type 1 diabetes.
Nikolaos Papanas, Maria Demetriou, Efstratios Maltezos. World J Diabetes 2010
Nikolaos Papanas, Maria Demetriou, Efstratios Maltezos. World J Diabetes 2010
50
Perspectives on the metabolic management of epilepsy through dietary reduction of glucose and elevation of ketone bodies.
Amanda E Greene, Mariana T Todorova, Thomas N Seyfried. J Neurochem 2003
Amanda E Greene, Mariana T Todorova, Thomas N Seyfried. J Neurochem 2003
25
A clinical screening tool identifies autoimmune diabetes in adults.
Spiros Fourlanos, Christine Perry, Mark S Stein, Jim Stankovich, Leonard C Harrison, Peter G Colman. Diabetes Care 2006
Spiros Fourlanos, Christine Perry, Mark S Stein, Jim Stankovich, Leonard C Harrison, Peter G Colman. Diabetes Care 2006
25
The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.
K Pafili, E Maltezos, N Papanas. Expert Opin Investig Drugs 2016
K Pafili, E Maltezos, N Papanas. Expert Opin Investig Drugs 2016
25
Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes.
Robert R Henry, Payal Thakkar, Cindy Tong, David Polidori, Maria Alba. Diabetes Care 2015
Robert R Henry, Payal Thakkar, Cindy Tong, David Polidori, Maria Alba. Diabetes Care 2015
25
Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes.
Sunder Mudaliar, Debra A Armstrong, Annie A Mavian, Robin O'Connor-Semmes, Patricia K Mydlow, June Ye, Elizabeth K Hussey, Derek J Nunez, Robert R Henry, Robert L Dobbins. Diabetes Care 2012
Sunder Mudaliar, Debra A Armstrong, Annie A Mavian, Robin O'Connor-Semmes, Patricia K Mydlow, June Ye, Elizabeth K Hussey, Derek J Nunez, Robert R Henry, Robert L Dobbins. Diabetes Care 2012
25
Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.
Kellee M Miller, Nicole C Foster, Roy W Beck, Richard M Bergenstal, Stephanie N DuBose, Linda A DiMeglio, David M Maahs, William V Tamborlane. Diabetes Care 2015
Kellee M Miller, Nicole C Foster, Roy W Beck, Richard M Bergenstal, Stephanie N DuBose, Linda A DiMeglio, David M Maahs, William V Tamborlane. Diabetes Care 2015
25
European Association for the Study of Diabetes 51st Annual Meeting.
Helen X Gao, Emily E Regier, Kelly L Close. J Diabetes 2016
Helen X Gao, Emily E Regier, Kelly L Close. J Diabetes 2016
100
SGLT-2 INHIBITORS AS ADJUNCT THERAPY IN TYPE 1 DIABETES: REASON FOR HOPE AND CAUTION.
Wendy Lane. Endocr Pract 2016
Wendy Lane. Endocr Pract 2016
100
The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes.
Helena W Rodbard, Anne L Peters, April Slee, Anjun Cao, Shana B Traina, Maria Alba. Diabetes Care 2017
Helena W Rodbard, Anne L Peters, April Slee, Anjun Cao, Shana B Traina, Maria Alba. Diabetes Care 2017
25
Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin.
Sunder Mudaliar, Robert R Henry, Guenther Boden, Steven Smith, Alexandros-Georgios Chalamandaris, Dominique Duchesne, Nayyar Iqbal, James List. Diabetes Technol Ther 2014
Sunder Mudaliar, Robert R Henry, Guenther Boden, Steven Smith, Alexandros-Georgios Chalamandaris, Dominique Duchesne, Nayyar Iqbal, James List. Diabetes Technol Ther 2014
25
Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.
Atsuo Tahara, Eiji Kurosaki, Masanori Yokono, Daisuke Yamajuku, Rumi Kihara, Yuka Hayashizaki, Toshiyuki Takasu, Masakazu Imamura, Qun Li, Hiroshi Tomiyama,[...]. J Pharm Pharmacol 2014
Atsuo Tahara, Eiji Kurosaki, Masanori Yokono, Daisuke Yamajuku, Rumi Kihara, Yuka Hayashizaki, Toshiyuki Takasu, Masakazu Imamura, Qun Li, Hiroshi Tomiyama,[...]. J Pharm Pharmacol 2014
25
Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
Chantal Mathieu, Bernard Zinman, Joanna Uddén Hemmingsson, Vincent Woo, Peter Colman, Erik Christiansen, Martin Linder, Bruce Bode. Diabetes Care 2016
Chantal Mathieu, Bernard Zinman, Joanna Uddén Hemmingsson, Vincent Woo, Peter Colman, Erik Christiansen, Martin Linder, Bruce Bode. Diabetes Care 2016
25
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
J P H Wilding, V Woo, K Rohwedder, J Sugg, S Parikh. Diabetes Obes Metab 2014
J P H Wilding, V Woo, K Rohwedder, J Sugg, S Parikh. Diabetes Obes Metab 2014
25
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.